[go: up one dir, main page]

WO2015030567A1 - Améliorations apportées à une formulation auxiliaire pour contrecarrer les effets indésirables de traitements contre le cancer et de traitements contre certaines maladies virales - Google Patents

Améliorations apportées à une formulation auxiliaire pour contrecarrer les effets indésirables de traitements contre le cancer et de traitements contre certaines maladies virales Download PDF

Info

Publication number
WO2015030567A1
WO2015030567A1 PCT/MX2013/000103 MX2013000103W WO2015030567A1 WO 2015030567 A1 WO2015030567 A1 WO 2015030567A1 MX 2013000103 W MX2013000103 W MX 2013000103W WO 2015030567 A1 WO2015030567 A1 WO 2015030567A1
Authority
WO
WIPO (PCT)
Prior art keywords
dilution
chemotherapy
auxiliary
post
pharmaceutical formulation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/MX2013/000103
Other languages
English (en)
Spanish (es)
Inventor
Juan Alberto ZAMARRIPA BLAS
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Priority to PCT/MX2013/000103 priority Critical patent/WO2015030567A1/fr
Publication of WO2015030567A1 publication Critical patent/WO2015030567A1/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/42—Phosphorus; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/14—Alkali metal chlorides; Alkaline earth metal chlorides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/56—Materials from animals other than mammals
    • A61K35/618—Molluscs, e.g. fresh-water molluscs, oysters, clams, squids, octopus, cuttlefish, snails or slugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
    • A61K36/282—Artemisia, e.g. wormwood or sagebrush
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics

Definitions

  • the present invention relates generally to the field of medicine. More particularly, it refers to the use of a diluted drug formulation made on the traces of the multiple components of plant origin that include one or more elements of each of the following classes of plants: Magnoliopsidas, Liliopsidas, Equisetopsidas, Lycopodiopsidas and Pinopsidas; of animal origin where we find insects, nosodes and organotherapeutics; and of mineral origin (trace elements and diluted inorganic chemical compounds of mineral origin) and by other organic substances that include vitamins (coenzymes or cofactors), Krebs cycle catalysts and amino acids, useful to minimize or alleviate the different adverse effects that occur later to the administration of chemotherapy and radiotherapy in the treatment of cancer, as well as the side effects caused by antiviral medications and interferons.
  • Chemotherapy treatments are aimed at destroying cancer cells, unfortunately they cannot distinguish them from healthy cells, causing adverse effects that can be from a series of discomforts that decrease the patient's quality of life, producing such harmful effects that they put risk the continuity of the treatment and the patient's life itself.
  • the most common symptoms range from: hair loss, nausea, vomiting, diarrhea, constipation, myalgia, arthralgia, even severe tachycardias.
  • Radiation therapy offers important advantages for local and regional treatment of malignant processes. Radiation therapy produces its biological effect through the formation of pairs of reactive oxygen ions or metabolites such as superoxide, H202, or hydroxyl radicals, products that cause DNA breakdown, which if not repaired can lead to cell death. Among other recognized late effects of radiation therapy, it is worth mentioning the mutagenesis and carcinogenesis produced by the sub-lethal effects of DNA radiation Radiation therapy can be administered in the form of electromagnetic waves, such as X-rays or gamma rays or as a current or flow of particles such as heavy ions, protons, neutrons, pi mesons or electrons. The characteristics of each of these forms of radiation have important implications for their clinical use.
  • Radiation therapy while eliminating diseased cells, can affect healthy tissues near the treatment area and as a consequence side effects may occur, due to the fact that in its path through the body, radiation transmits part of its energy to the Cell DNA, the genetic code molecule, causing irreversible damage that ends up killing the cell. This happens in both normal and cancer cells.
  • the drugs of the Interferon group have a negative influence on the liver and the whole organism.
  • 75-80% of patients treated with this type of medicine develop a Toxic hepatitis, whose evolution is dangerous for the patient's life.
  • the frequency and intensity of adverse reactions of antiviral medications cause additional liver overload, producing adverse effects such as: hepatic steatosis (excess fat in the liver), hepatomegalies (increased liver volume), hepatitis (inflammation of the liver), proximal renal tubular alteration, lactic acidosis (accumulation of lactic acid in the blood) and peripheral neuropathy (involvement of the peripheral nerves).
  • the antiviral drugs used against viral hepatitis and HIV have similar adverse effects with some types of chemotherapies used as a base treatment for some types of cancers.
  • Both therapeutic groups in both antiviral drugs and chemotherapy often share the same enzymatic pathways and cellular receptors as a mechanism of pharmacological action which these can compete with each other and can block enzymes or substrates that participate in the different pathways or sites of cellular metabolism, in the cell cycle (controlling or affecting the manipulation of the structure of the RNA and DNA necessary for cell replication), or on the cell membrane; producing that there is a lower capacity of cellular response and reflected in the metabolism of the same, which present metabolic dysfunctions and blockages in the energy producing systems manifesting itself with physical changes in the quality of life.
  • the present invention provides a route for relief or elimination of toxicity by chemotherapy, radiotherapy and by antiviral drugs and interferons, involving administering a composition comprising dilutions of multiple traces of different components of plant origin that include one or more elements of each of the following classes of plants: Magnoliopsidas, Liliopsidas, Equisetopsidas , Lycopodiopsidas and Pinopsidas; of animal origin where we find insects, Nosodes and Organotherapeutics; and of mineral origin (trace elements and diluted inorganic chemical compounds of mineral origin) and by other organic substances that include vitamins (coenzymes or cofactors), catalysts of the Krebs cycle and amino acids, made using diluted components which are combined, generating a effect within our body, so it finally acts as an antihomotoxic medicine that helps improve
  • Classic homeopathy uses unit medicines, of which only a part are really remedies consisting of a single substance (for example, sulfur, mercury, arsenic, etc.) or are plant extracts that contain a very complex mixture of various substances.
  • the so-called repertoires lists of symptoms produced by medications) that makes it easier for homeopaths to choose the most appropriate medications in each case.
  • Antihomotoxic drugs mainly constitute mixtures of substances in low or medium potency (homeopathic dilutions).
  • homotoxicology in addition to using classic homeopathy medicines, uses completely new homeopaths such as: Nodes: viral, bacterial, vaccines, tissues or organs with pathological alterations, blood secretions and endocrine secretions, homeopathic allopathic medicines, intermediate catalysts: citric acid cycle acids, quinones and others; and organopreparations: elaborated homeopathically from organic tissues from healthy pigs. Also in the same antihomotoxic medicine incorporates different substances and in different dilutions.
  • an antihomotoxic drug is capable of stimulating the structure of the organ, the function and the mental aspect of the individual, as well as the stimulation of blocked enzyme systems in degenerative diseases, the stimulation of defensive antitoxic mechanisms and generates an effect of tropism on damaged organs; he works on the # theory of the six phases that Reckeweg formulated, where he shows the chronological development of different symptoms of a disease in the framework of baseline regulation. Each phase is transformed fluidly into another and typical guide symptoms of each phase are observed.
  • antihomotoxic medicine serves as a bridge between conventional allopathic medicine and homeopathy, in such a way that it is possible to homeopathize allopathic drugs thus removing its toxic effect and it can be combined with other components safely.
  • Homotoxicology is the branch of medicine that studies in a scientific way, diseases caused by exogenous toxins (which are acquired from outside the body) and endogenous (those produced by the same organism) that block the cellular metabolic function of tissues and the organs of the human being. (Antihomotoxic Medicine Vol. I Principles, Clinical, Practical, 2004).
  • the present invention given the nature of its content and pharmacodynamic form as it acts, allows the patient's quality of life to be raised, eliminating or greatly diminishing the consequences of chemotherapy, radiotherapy and antiviral medications and interferons. It has the great advantage that can be combined with drugs that the patient may be taking for cancer, viral hepatitis, HIV or other diseases, without taking away from these drugs.
  • the first is that it manages to combine 101 different components that act independently, stimulating various organs and tissues at the cellular level to prepare and recover from the toxic effects of Chemotherapy, receiving the least possible damage, and consequently greatly reducing adverse effects.
  • this product yields benefits at the cellular, tissue, organic and mental levels, which avoids the cumulative deterioration in the patient's level of health by allowing him to continue his chemotherapy treatment without interruptions.
  • the present invention aims at the preparation of a diluted medicated formulation comprising a mixture of dilutions of plant origin that include one or more elements of each of the following classes of plants: Magnoliopsides, Liliopsides, Equisetopsides, Lycopodiopsides and Pinopsides; of animal origin where we find insects, Nosodes and Organotherapeutics; and of mineral origin (trace elements and diluted inorganic chemical compounds of mineral origin) and by other organic substances that include vitamins (coenzymes or cofactors), catalysts of the Krebs cycle and amino acids, for the relief of symptoms of dizziness, nausea, vomiting, weakness of the body, headache, pain of body, feeling of heaviness of the head, feeling of heaviness of the body, sleep, diarrhea, constipation, bone and joint pain, chest and / or throat pain when eating, mouth sores, loss of appetite and gas or flatulence, which they occur after the administration of chemotherapy and / or radiotherapy in the treatment of cancer, as well as after the administration of antiviral drugs and
  • the present invention also aims at a medicament obtained from a diluted medicated formulation acceptable for the relief of symptoms of dizziness, nausea, vomiting, weakness of the body, headache, body aches, heaviness, headache, sensation of heaviness of body, sleep, diarrhea, constipation, bone and joint pain, chest and / or throat pain when eating, canker sores, loss of appetite and gas or flatulence, caused by the application of chemotherapy, radiotherapy and treatments with antiviral drugs and interferons, comprising a mixture of effective dilutions of plant origin that include one or more elements of each of the following classes of plants: Magnoliopsidas, Liliopsidas, Equisetopsidas, Lycopodiopsidas and Pinopsidas; of animal origin where we find insects, Nosodes and Organotherapeutics; and of mineral origin (trace elements and diluted inorganic chemical compounds of mineral origin) and by other organic substances that include vitamins (coenzymes or cofactors), catalysts of the Krebs cycle and amino acids.
  • the technique for making the dilutions necessary to obtain the formulation according to the present invention corresponds to the conventional technique of manufacturing homeopathic formulations according to the Homeopathic pharmacopoeia of the United States, which consists in diluting in pre-established proportions for each substance, a part of solute in others of solvent and applying to this dilution vigorous succuctions.
  • the decimal scale is used where the dilution factor is 10, that is 1 part of dyeing in 9 parts of solvent, it is shaken vigorously and the second decimal dilution (2x) is obtained, considering that the tincture of which it is made corresponds to the first decimal dilution (1x). It continues like this, in the same way until the desired decimal dilution is obtained, always taking into account that to obtain a higher dilution it is always necessary to start from the previous dilution.
  • the formula is mainly composed of Angelicae gigantis and Cnidium root for medicinal use, whose process involves obtaining an extract from an infusion in hot water, characteristics that are not used in our invention since it is based on dilutions and not It contains none of the mentioned elements.
  • WO 2013 048452 International patent application publication claiming the invention of a small molecule modulating the tumor necrosis alpha factor that reduces nephrotoxicity and hepatotoxicity caused by chemotherapy and radiotherapy treatments. Our formulation not only reduces these adverse effects but others that cause various unwanted manifestations in patients, allowing them to continue treatment.
  • WO 2009 084732 International patent application publication that reinvindicates a preparation based on potassium citrate and sodium citrate, used as a therapeutic agent to treat anemia, which is one of the adverse effects of treatment with combinations of Interferon and Rivavirine. Unlike this preparation, our formula fights a plurality of additional adverse effects, caused by therapies with interferons and antivirals.
  • WO 2008 021536 International patent publication describing a method to reduce unwanted adverse events in treatments with interferon alfa and interferon beta.
  • the method consists mainly in the application of interferon tau orally simultaneously with the parenteral application of interferon alpha and interferon beta.
  • This method particularly seeks to obtain a better response of the organism to interferon treatments, however a better response does not translate into a comprehensive improvement in the feeling of physical well-being of the patient, it improves that if it is achieved with the use of our formula when used simultaneously with the application of alpha and beta interferons.
  • FIG. 1 Shows a graph of the percentage of men and women participating in the study group of patients diagnosed with cancer who were undergoing chemotherapy, radiotherapy or both.
  • FIG. 2 Shows the age distribution of the group of patients diagnosed with cancer who participated in the study.
  • FIG. 3 Shows the distribution by type of cancer of the patients who participated in the study.
  • FIG. 4 It shows a comparative graph of the symptomatology of adverse effects manifested by patients diagnosed with cancer, without administering the formulation and that manifested after administering the formulation.
  • FIG. 5 It shows a graph of the results at the end of the study with the group of patients diagnosed with cancer, where the number of patients under treatment and those without tumor activity (absence of disease, according to cabinet studies) can be seen.
  • FIG. 6 It shows a comparative graph of the symptomatology of adverse effects manifested by patients diagnosed with HIV, without administering the formulation and that manifested after administering the formulation.
  • the present invention is a formulation composed of 101 ingredients of multiple different traces that are in different dilutions, ranging from the first dilution (1x) to the twelfth dilution (200x) making a total of 141 dilutions, of which 36% include source components vegetable that includes one or several elements of each of the following kinds of plants: agnoliopsides, liliopsides, equisetopsidas, lycopodiopsidas and pinopsidas, 14% are of animal origin where we find insects, nosodes and organotherapeutics; and 50% of mineral origin (trace elements and diluted inorganic chemical compounds of mineral origin) and other organic substances that include vitamins (coenzymes or cofactors), catalysts of the Krebs cycle and amino acids.
  • Acidum acetylosalicylium (acetylsalicylic acid) at the tenth dilution (10x) is applied to conditions of weakness and muscle pain that may occur after chemotherapy.
  • Avena sativa (oatmeal) at the sixth dilution (6x) is applied in nervous exhaustion due to chronic disease or by the application of chemotherapy.
  • Beta vulgaris conditivo (Betabel) at the fourth dilution (4x), is a reactivator of cellular respiration that can be blocked after chemotherapy.
  • Cynara scolymus (artichoke) at the sixth dilution (6x), participates in the stimulation of the liver's detoxifying and natural diuretic function in post-chemotherapy edema.
  • Hidrastis canadensis hydroastis or gold seal
  • Hidrastis canadensis hydroastis or gold seal
  • Ipecacuanha ipecacuana
  • 4x fourth dilution
  • Ipecacuanha ipecacuana
  • Veratrum album vedegambre
  • 10x tenth dilution
  • Veratrum album vedegambre
  • Veratrum album vedegambre
  • twelfth dilution 200x
  • lymphatic circulation disorders due to radiotherapy.
  • the components of animal origin used in the formulation are remedies prepared by raw materials that are of animal origin where it can be used: dissected animals (gallbladder cantharis) is made from the dry dust of the insect and in some other cases, parts or secretions of them as Apisinum (bee venom).
  • organotherapy which is a method that uses remedies prepared based on healthy animal organs where they are diluted and energized to produce a specific stimulation on the affected human organ.
  • the principle of the identical organ is used, complementing with the homeopathic principle of similarity.
  • the organ is administered in microdoses (infinitesimals) that causes only one activation reaction of the specific organ, without affecting other organs.
  • NOSODES 1 Of 1 mg. at 5 mg of Bacterium Coli (Escherichia coli) at the thirteenth dilution (13x) auxiliary in urinary tract infections that may occur after the administration of chemotherapy.
  • Coxsackie Virus A Coxsackie Virus
  • 8x auxiliary in mucosal, urinary tract or upper respiratory tract conditions such as post-chemotherapy pseudo-influenza.
  • Duodenum duodenum
  • auxiliary to treat inflammation of the duodenum after chemotherapy application 3.
  • Adrenal gland (adrenal gland) at the tenth dilution (10x) allows hormonal balance at the post-chemotherapy cell level.
  • Pancreas at the tenth dilution (10x) organotropism stimulates the cells of the pancreas for detoxification after chemotherapy.
  • Urinary Vesica urinary bladder
  • 8x eighth dilution organotropism to the urinary bladder in its function for post-chemotherapy detoxification.
  • the components of mineral origin used in the formulation are extracted from metal ions (trace elements) and diluted inorganic chemical compounds of mineral origin and contain:
  • Hepar sulfuris calcium carbonate and sulfur flowers
  • Hepar sulfuris calcium carbonate and sulfur flowers
  • 1 mg at 5 mg of Mercurius sublimatus corrosivus (mercury chloride or mercury bichloride, corrosive sublimed) at the eighth dilution (8x) auxiliary in frequent urination to very painful urination, with burning in the post-chemotherapy urethra.
  • the other organic substances used in the formulation are composed of vitamins, Krebs cycle catalysts and amino acids. These elements together with those of mineral origin make up the formulation in 50%, participating in the cellular metabolic processes in a catalytic way as in the framework of cellular respiration and obtaining energy (cycle of krebs), unblocking process and cellular detoxification and contain: Vitamins (coenzymes or cofactors) and Krebs cycle catalysts
  • Methylgfyoxalum methyl glyoxal
  • Methylgfyoxalum methyl glyoxal
  • Nicotinamidum (nicotinamide) at the sixth dilution (6x) co-factor for enzymatic functions and energy production post-chemotherapy and post-radiotherapy.
  • Trichinoylum (inositol) at the tenth dilution (10x) favors post-chemotherapy cell detoxification.
  • the present invention is a formulation elaborated by the combination of the traces of 101 different elements which are of natural origin, where to each of them the principles of drug dilution are applied, having the specificity of dilution and weight in milligrams to remove the symptoms and / or specific signs of the most common adverse effects of chemotherapy such as: nausea, vomiting, headache, myalgia, asthenia and adinamia.
  • the present invention in its function in a global way integrated by the traces of the multiple elements, when entering the interior of the organism by the sublingual route is not separated, since it works together in groups, and these act at the same time in different spheres of action that often share chemicals and receptors. In this way we can place the different groups of elements that are participating according to the sphere of action as:
  • toxins When toxins are able to bind to cellular structures and DNA, the entry and exit of the flow into the cell is blocked by natural self-protection mechanisms, therefore metabolic processes are greatly affected since the basic elements for performing or completing the process of basal metabolism of the organism are limited, therefore the common final pathway of cellular toxicity to often comes from the interruption of cellular respiration, certain toxins are able to directly decouple cellular respiration but above all the mechanism is through mitochondrial DNA damage. Many drugs, such as antiretroviral drugs used in AIDS, and chemotherapeutics can also cause damage to mitochondrial DNA.
  • the formulation is useful as it contains the krebs cycle catalysts and these activate a respiratory chain transporter protein, managing to unlock and be able to participate effectively in the treatment of cellular toxicity.
  • quinones, glyoxal and methylglyoxalum are capable of depolymerizing compounds such as toxins when they are attached to the matrix structures and together with the rest of the trace elements that have this same detoxification and drainage function, they also do deep cell cleaning effect.
  • the cellular matrix occupies all the extracellular spaces (spaces that exist between the cells) of the organism and is also called extracellular space with a gelatinous consistency and chemically constituted by a complex network of sugars and proteins that are polymerated and these are attached to the cell membrane which contains all membrane receptors, cell adhesion molecules, etc.
  • extracellular space is the means by which cells obtain their nutrients and they eliminate their toxins due to normal metabolism; and this makes it a transit route, since the cellular metabolism that is carried out inside the cell (cellular mitochondria) interacts with the structures that are outside the cell (extracellular space or matrix) such as blood vessels (arterial and venous), lymphatic and free endings of vegetative nerve fibers, make it directly connected to the central nervous system. Therefore, since the extracellular space is a pre-cell element, it constitutes a molecular filter in all cells or cell complexes and therefore it is of utmost importance to keep it as clean as possible of toxins for its proper functioning.
  • the present invention When the present invention reaches the hepatocyte (the main cell in the liver responsible for the detoxifying action), it helps to activate the processes of elimination of toxins (metabolites of chemotherapy), hepatic steatosis, hepatomegaly, hepatitis (adverse effects of antiviral drugs) and others that keep their functioning in imbalance, since this organ is one of the most important detoxification in the body, and metabolically the most complex (participates in the metabolism of cholesterol, glycolysis and glyconeogenesis, as well as providing coagulation factors and many plasma proteins, and the performance of hormones and fats).
  • Phase 1 includes the enzymes of the P450 enzyme system, which is a collection of mixed-function oxidases.
  • Fat-soluble toxins are changed through oxidation, reduction and hydrolysis, so that they are more soluble in water and their excretion can be facilitated through the kidneys in a water-soluble way and for certain cofactors to fulfill their action and this is where
  • the present invention works, providing them with trace elements, amino acids, vitamins and substances such as NADH; and also participate in the phase 2 pathway or conjugation pathway using substances rich in sulfhydryl groups to metabolize toxins, a number of these substances such as cysteine and taurine, as well as glutathione (which is formed from of glycine, glutamine and cysteine under the influence of a setenium-dependent enzyme) that also act as free radical scavengers and heavy metal chelators.
  • toxins that have been made soluble in water by the liver are excreted, as well as some medications and heavy metals.
  • Excretion through the kidney is an important part of the detoxification process, and in the present invention renal excretion function is supported through traces of elements that act in its sphere of action at the renal level such as sarsaparilla, equisetum hyemale, Berberis vulgaris, solidago virgaurea, elements that will also support the function of the adrenal glands, and thus the plant materials that have been used classically in botanical medicine to support renal function.
  • nosodes and proteins of bee venom make it candidates for immunomodulation, such as organotherapeutics that stimulate the repair of the structure of the damaged organ by a mechanism of the tropism effect for its recovery.
  • the group of energy producing systems corresponds to the traces of the intermediate catalysts that participate as inductors and activators related to the cycle of krebs or citric acid, being the most important source of energy of the cellular metabolism and that when this is affected by the toxic load of some medications, in this case the chemotherapeutic ones, the alterations of the enzymatic systems are presented , since many conventional drugs base their principle of action on the influence they exert on enzymes.
  • intermediate catalysts is broader, which includes: a) the catalysts in the strict sense (enzymes), which are substances that participate in the repair of the balance of chemical reactions , but without entering themselves into their process mechanism; b) the corresponding substrates, intermediates and cofactors (which are trace elements and vitamins), where the catalysts are only activated by these cofactors, that is to say they become specifically functional.
  • malic acid (acidum DL malicum)
  • cerium oxalate cerium oxalicum
  • magnesium gluconate magnesium gluconicum
  • magnesium orotate magnesium oroticum
  • the content of the traces of elements that are participating in the sphere of action at the nervous system level are because they have also been found other effects to treat a wide range of ailments, among which popularly include very specific properties such as sedatives , anticonvulsants to a lesser extent, without affecting the essential cognitive functions and orientation in time, place and space at the mental level, producing more an effect of emotional relaxation as a neuroprotective effect against global brain damage caused by oxidative stress induced by Chemotherapies and similarly generates a secondary muscle relaxant effect from a central level (central nervous system).
  • striated muscles skeletal movements are produced and the mobility of the different parts of the body is due to them; while the smooth muscle is in almost all internal organs of the body such as the gastrointestinal tract, gallbladder, urinary bladder, ureters, etc., and is usually different from that of one organ to another, that is to say in many different ways, even in reactions to the different types of stimuli, characteristics of their innervation and function.
  • the nervous system interacts with the muscle through a specialized structure called neuromuscular plaque, and in smooth muscle cells this plaque is not present, but instead there are terminal nerve branches that have vesicles and that these contain inside neurotransmitters that are released in the extracellular space; This is where the molecules diffuse to interact with the receptors of the smooth muscle cell membranes, then the contraction impulses sweep over the smooth muscle cells, because the cells communicate through the junctions. Smooth muscles mainly react to the autonomic nervous system stimuli through the autonomic receptor binding.
  • A) Cholinergic receptors use acetylcholine and are subdivided into receptors: muscarinic or acetylcholine-muscarinic receptors (mAChR) such as M1, M2, 3 type found in smooth muscle, 4 M5 are found in the brain. And in nicotinics or acetylcholine-nicotinic receptors (nAChR) these can increase or decrease the activity of the effector cells.
  • mAChR acetylcholine-muscarinic receptors
  • nAChR acetylcholine-nicotinic receptors
  • Adrenergic receptors use catecholamines such as: epinephrine and norepinephrine.
  • the present invention contains traces of elements that are antagonists of acetylcholine such as scopolamine and atropine found in Belladonna Atropa, all of which are tertiary or quaternary antimuscarinic aminos, which block the action of acetylcholine in the receptor. That can be used to control the secretion of saliva and gastric acid, slow intestinal motility and prevent vomiting, they also act as powerful antimuscarinic antispasmodics also used to block receptor 3, which is found in smooth muscle of hollow organs such as the digestive and respiratory system.
  • the appearance of skeletal muscle spasm is complex, and has its origin not only in the muscle itself, but also in the centers of the highest pain. Remission to deeper tissues is based on central nervous mechanisms.
  • the neuromuscular junction in skeletal muscle is a highly specialized structure, where acetylcholine is the final neurotransmitter, however, not through muscarinic and nicotinic receptors as in the case of smooth muscle.
  • acetylcholine is the final neurotransmitter, however, not through muscarinic and nicotinic receptors as in the case of smooth muscle.
  • Acetylcholine binds to cholinergic receptors (acetylcholine), which opens up ion channels especially sodium channels, which reduces the membrane potential that results in muscle contraction.
  • acetylcholine When there is injury to the muscle (in this case toxic load) the pain receptors are sensitive, reactive vessel substances are released causing edema, venous stasis and ischemia. This in turn leads to the loss of ATP, with the breakdown of the calcium pump in the muscle, which is responsible for the relaxation of muscle fibers the result is a spasm.
  • the higher centers such as the spinal cord and the middle brain, which are structures that change and lose their typical inhibitory influence on pain; This will lead to an increase in pain perception.
  • TH1 cells are activated in the inflammation and secretion of inflammatory cytokines and chemokines and while apisinum has an action in the inflammatory cascade by inhibiting COX-1 and COX-2, as well as LOX5 enzymes, which reduces formation of prostaglandins that act as chemical mediators.
  • acetylsalicylic acid (Acidum acetylosalicylicum)
  • sarcolactic acid (acidum sarcolacticum)
  • Gastrointestinal disorders represent one of the most common reasons why patients seek medical attention, since these are nausea, vomiting, stomatitis with old mouth ulcerations, diarrhea or constipation, abdominal distension, flatulence, abdominal cramps ranging from minimum to be disabling, etc.
  • probiotic bacteria form a passive barrier that prevents harmful substances from coming into contact with the epithelial layer.
  • probiotic bacteria also have other functions, such as the fuel supply of mucous cells as well as contributing to immune competence.
  • the absorption of particles through the epithelial layer is possible in 2 ways: through the transce ⁇ ular epithelial cells, or paracellular through the narrow junction.
  • the narrow junction has a complex physiology and only particles of a diameter are allowed to apply to certain sizes to enter, which varies in size in different physiological and pathological conditions.
  • the mucosal immune system is the next line of defense and guarantees special attention for several reasons. Not only most of our competent immune cells located in Peyer's plaques, but the intestinal immune system also deals with antigens in a very specific way in order to develop oral tolerance to useful substances. This mechanism serves as a model for the immune modulating mechanism of our molecule's work in the immune assistance reaction.
  • the blood flow that forms is the next barrier, not only in the sense that it will carry residual toxins in the liver, but it seems that the endothelial layer also plays an important role in the permeability of the epithelial layer.
  • the liver is one of the main detoxification organs in the body as already mentioned above, and it is beneficial that all the blood that flows from the intestine into the liver through the portal vein therefore the liver has a role in the development of tolerance to certain foods and jointly carrying the toxic load of metabolites generated by chemotherapeutic drugs together with the rest of the organs and especially more evident in the gastrointestinal tract (matrix and urinary system) our molecule contains elements that They will be very useful for having a double function in both the liver and the intestine.
  • the intestinal immune system has developed a special immune response to these toxins, which response is oriented towards tolerance, mucosal surfaces have a large number of regulatory T cells, of which TH3 cells and suppressor T cells are the most important for this purpose.
  • TH3 cells are an important source of transforming growth factor beta and serves to restore the normal oscillatory balance between Th1 and Th2 cells.
  • Th2 cells secrete IL-10 and IL-4, which also regulate the low inflammatory response, the normal response of the intestinal immune system tends to be that of a regulation or a response to TH2 cells.
  • the Th3 cell is induced by small dilutions of amino acids contained in the present invention as trace elements of plants, poisons (apisinum), therapeutic organs and nosodes, which the clones of these cells (TH3 cell) will be attracted to chemokines to any site of inflammation that regulate a downward trend of TH1 cells and balance the ratio between Th1 / Th2, this regulatory action induced by the present invention, can be used not only in autoimmunity to induce tolerance to Affected tissues after administration of chemotherapy, but also to regulate with a downward trend in inflammation, not only in the intestine, but for the entire organism.
  • pancreas pancreas
  • This medicine can be administered by different routes, mainly the sublingual, including oral, parenterally, as well as topically.
  • the preferred method of administration for the treated cases is orally, which is prepared in the form of a sublingual tablet obtained by impregnating a solid support with the diluted drug formulation mentioned above. Lactose is used as solid support. Said tablet containing 438.40 mg of active ingredient.
  • 1 or 2 tablets are dissolved under the tongue every 15 minutes for a period of 2 hours before chemotherapy, after chemotherapy dissolve 1 or 2 tablets every 15 minutes for 2 doses, continue with 1 or 2 tablets each 4 or 6 hours depending on the inconvenience for 7 days.
  • nausea and / or vomiting crisis take 1 or 2 tablets every 15 minutes until the symptoms disappear for a maximum period of 2 hours.
  • FIG. 6 shows the results obtained in a group of 9 patients infected with Human Immunodeficiency Virus (HIV) who agreed to be part of a protocol of research in 2009 (Dr. Enrique Gómez Bastidas. Amigo Program. Autonomous University of Baja California). This group of patients they were being treated with antiretroviral drugs, which also produce serious adverse effects to those who use them.
  • HIV Human Immunodeficiency Virus

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Inorganic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biotechnology (AREA)
  • Botany (AREA)
  • Medical Informatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Zoology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

L'invention concerne des améliorations apportées à une formulation pharmaceutique diluée comprenant au moins un constituant d'origine végétale, animale et minérale, de manière qu'elle renferme Abrotanum (aurone) comme constituant dilué d'origine végétale, Sepia comme constituant dilué d'origine animale et Phosphorus (phosphore) et Causticum Hahnemanni comme constituants dilués d'origine minérale. La formulation est utilisée pour contrecarrer et atténuer les effets indésirables de la radiothérapie et les effets indésirables des traitements par médicaments antiviraux et/ou interférons.
PCT/MX2013/000103 2013-08-30 2013-08-30 Améliorations apportées à une formulation auxiliaire pour contrecarrer les effets indésirables de traitements contre le cancer et de traitements contre certaines maladies virales Ceased WO2015030567A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
PCT/MX2013/000103 WO2015030567A1 (fr) 2013-08-30 2013-08-30 Améliorations apportées à une formulation auxiliaire pour contrecarrer les effets indésirables de traitements contre le cancer et de traitements contre certaines maladies virales

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/MX2013/000103 WO2015030567A1 (fr) 2013-08-30 2013-08-30 Améliorations apportées à une formulation auxiliaire pour contrecarrer les effets indésirables de traitements contre le cancer et de traitements contre certaines maladies virales

Publications (1)

Publication Number Publication Date
WO2015030567A1 true WO2015030567A1 (fr) 2015-03-05

Family

ID=52587009

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/MX2013/000103 Ceased WO2015030567A1 (fr) 2013-08-30 2013-08-30 Améliorations apportées à une formulation auxiliaire pour contrecarrer les effets indésirables de traitements contre le cancer et de traitements contre certaines maladies virales

Country Status (1)

Country Link
WO (1) WO2015030567A1 (fr)

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2013342A6 (es) * 1987-07-31 1990-05-01 Besnouin Didier Procedimiento para preparar composiciones farmaceuticas a base de ingredientes seleccionados principalmente entre alcohol, fenol, polvo de cantarida, yodo y fosforo.
WO2003022294A2 (fr) * 2001-09-11 2003-03-20 Josef Beuth Extrait obtenu a partir de artemisia abrotanum l. (aurone)
US20080279902A1 (en) * 2007-05-09 2008-11-13 Henry Steven Luria Delivery System And Method To Deliver Homeopathic Complexes Comprising Homeopathic Colored Pigment Products For Cosmetic Use
MX2010011715A (es) * 2008-04-29 2010-12-06 Oswal Gunvant Devichand Una formulacion homeopatica.

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2013342A6 (es) * 1987-07-31 1990-05-01 Besnouin Didier Procedimiento para preparar composiciones farmaceuticas a base de ingredientes seleccionados principalmente entre alcohol, fenol, polvo de cantarida, yodo y fosforo.
WO2003022294A2 (fr) * 2001-09-11 2003-03-20 Josef Beuth Extrait obtenu a partir de artemisia abrotanum l. (aurone)
US20080279902A1 (en) * 2007-05-09 2008-11-13 Henry Steven Luria Delivery System And Method To Deliver Homeopathic Complexes Comprising Homeopathic Colored Pigment Products For Cosmetic Use
MX2010011715A (es) * 2008-04-29 2010-12-06 Oswal Gunvant Devichand Una formulacion homeopatica.

Similar Documents

Publication Publication Date Title
CN103446385B (zh) 一种治疗糖尿病并发症的中药制剂
CN103430903B (zh) 制备机会性感染和慢性消耗性疾病非人动物模型的方法及利用该模型筛选的药物
CN102106937A (zh) 一种用于治疗银屑病的药物
CN102579999A (zh) 一种治疗癌性发热的药物及其制备方法
CN102671046B (zh) 一种治疗慢性阑尾炎的中药
WO2015030567A1 (fr) Améliorations apportées à une formulation auxiliaire pour contrecarrer les effets indésirables de traitements contre le cancer et de traitements contre certaines maladies virales
CN104146999B (zh) 冬凌草甲素和多烯紫杉醇减毒增效抗肿瘤药物组合物及其应用
CN103169838B (zh) 一种治疗乙型肝炎的药物
Karamanou et al. Arsenic powder in the treatment of cancer: the invention of French physician Pierre Alliot (1610–1685)
CN102846750B (zh) 风痛宁复合制剂及其制备方法
CN103550446B (zh) 一种外用治疗类风湿关节炎的中药组合物及其应用
CN104857422B (zh) 治疗大肠癌的组合物及用于制备治疗大肠癌药物的用途
CN103055122B (zh) 预防冠脉支架植入术后再狭窄的药物及其制备方法
CN102327498A (zh) 含有紫杉醇浸膏的抗癌新药
CN106668061B (zh) 一种含有顺铂的抗癌药物组合物
CN116440232B (zh) 一种预防及治疗肿瘤相关手足麻木痹痛的中药组合物
CN102743589B (zh) 一种治疗嗜食大蒜型滴虫性阴道炎的中药洗剂制备方法
CN102626479B (zh) 治疗陈年风湿骨病外用中草药组合物
Mirza A Review on the Chemical versus Alternative Treatments of Leukemia
CN100525783C (zh) 使君子或其提取物在制备促进排铅作用中药制剂中的应用
CN100482258C (zh) 骨络气血通剂
Chen et al. Discussion on the prevention and treatment of COVID-19 by Zhuang Medicine
CN119139380A (zh) 一种治疗热症的药物组合物及其制剂与应用
CN101361775A (zh) 一种治疗肝癌的中药冻干粉针剂
CN105832946A (zh) 一种治疗人类癌症的药物及其生产方法

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 13892562

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 13892562

Country of ref document: EP

Kind code of ref document: A1